Minovia Therapeutics

A clinical-stage international biotechnology research company focused on treatment innovation for mitochondrial disease.

[Robert Lufkin MD @robertlufkinmd]

The strange evolution of mitochondria.

https://t.co/KV92mHp6vC

@Minovia_tx

[Progress, Potential, And Possibilities @ProgressPotent1]

Harnessing The Therapeutic Power Of Mitochondria - Dr. Natalie Yivgi-Ohana, Ph.D. - CEO, Minovia Therapeutics - @Minovia_tx @ProgressPotent1 @irat1onal @Countdown4ACure @sheba_medical @CoreIR_ @audreyanna_04 #MitochondrialDysfunction #RareDiseases #Aging #Longevity #MitochondrialAugmentationTechnology - https://t.co/LL5l5u4cMY

[Minovia Therapeutics @Minovia_tx]

At Minovia, we are pioneering the next generation of therapies with our Mitochondrial Augmentation Technology (MAT) platform. Our mission is to address both rare genetic mitochondrial diseases and age-related mitochondrial dysfunction disorders.

Learn more about our pipeline: https://t.co/UwVZZzNQtn

#Minovia #MitochondrialMedicine #InnovationInHealthcare #ClinicalDevelopment #MATPlatform

[Minovia Therapeutics @Minovia_tx]

Our collaborative approach—uniting expertise from both academia and industry—enables us to address the complex challenges posed by primary mitochondrial diseases and to develop innovative, personalized therapeutic solutions.

The MAT platform exemplifies our dedication to combining robust scientific discovery with scalable manufacturing processes, with the overarching goal of delivering meaningful therapies to patients affected by mitochondrial dysfunction.

#MinoviaTherapeutics #MitochondrialMedicine #ScientificExcellence #Collaboration #MATplatform

[Minovia Therapeutics @Minovia_tx]

Across the pipeline, Minovia’s Mitochondrial Augmentation Technology (MAT) has consistently shown a favorable safety profile, multi-system benefits, and biomarker-driven evidence of mitochondrial restoration, supporting both accelerated regulatory pathways and broad clinical potential.
‌
Learn more: https://t.co/UwVZZzNQtn
‌
#MitochondrialMedicine #RegenerativeMedicine #Longevity #CellTherapy #PearsonSyndrome #MDS #RareDisease #Biotech #Innovation #ClinicalTrials #PatientOutcomes

[Minovia Therapeutics @Minovia_tx]

At Minovia Therapeutics, our mission is fueled by a deep commitment to improving the lives of people affected by mitochondrial diseases.

We are advancing the field of mitochondrial medicine by developing innovative cell therapies designed to restore cellular energy and address the underlying causes of mitochondrial dysfunction. Working alongside leaders in science, clinical research, and patient advocacy, we are turning scientific discovery into tangible therapies with real impact.

#MinoviaTherapeutics #MitochondrialTherapy #CellTherapy #RareDiseases #BiotechInnovation #PrecisionMedicine #CountdownForACure #TheChampFoundation #UMDF

[Minovia Therapeutics @Minovia_tx]

Minovia Therapeutics is pleased to announce that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Technology (MAT) platform.

Read the full press release here: https://t.co/BtZYwW4I3U

#Minovia #Mitochondria #MitochondrialMedicine #MitochondrialAugmentationTechnology

[Minovia Therapeutics @Minovia_tx]

Minovia Therapeutics is pleased to share that our CEO and co-founder, Natalie Yivgi-Ohana, Ph.D., authored a thought leadership guest column in Drug Discovery Online titled “Harnessing Mitochondria: A New Frontier In Therapeutic Innovation.”

In this article, Dr. Yivgi-Ohana explores how mitochondrial dysfunction underlies a wide spectrum of rare and age-related diseases and why supplementing damaged mitochondria with healthy ones may open an entirely new class of therapies. She highlights Minovia’s mitochondrial Augmentation Technology (MAT) and our lead clinical-stage program, MNV-201, which is designed to introduce young, functional mitochondria into hematopoietic stem cells for patients with Pearson Syndrome and Myelodysplastic Syndrome (MDS).

Read the full column on Drug Discovery Online here: https://t.co/6ScttqTCE4

#MinoviaTherapeutics #Mitochondria #CellTherapy #MitochondrialMedicine #RareDisease #PearsonSyndrome #MDS #Biotech #ThoughtLeadership #DrugDiscovery

[Minovia Therapeutics @Minovia_tx]

Happy New Year from all of us at Minovia Therapeutics!

As we enter 2026, our team remains dedicated to advancing mitochondrial cell therapies to address the significant unmet needs of individuals living with mitochondrial dysfunction. May the coming year be marked by meaningful progress and scientific breakthroughs for the rare disease and mitochondrial communities

#MinoviaTherapeutics #HappyNewYear2026 #MitochondrialMedicine #CellTherapy #RareDiseaseCommunity #MitochondrialDisease

[Minovia Therapeutics @Minovia_tx]

Minovia Therapeutics is pleased to highlight Limor Lior, our Vice President of People & Culture, whose leadership is instrumental in advancing our commitment to excellence and innovation.

Limor holds an MSc in Biotechnology Engineering from the Technion – Israel Institute of Technology and is a certified coach, mediator, and group facilitator. Her strategic approach to people management and her dedication to fostering an empowering workplace culture continue to strengthen Minovia’s mission to deliver transformative mitochondrial therapies that improve human health and quality of life.

#MinoviaTherapeutics #LeadershipSpotlight #PeopleAndCulture #Biotechnology #ExecutiveLeadership

[Minovia Therapeutics @Minovia_tx]

As the year comes to a close, all of us at Minovia Therapeutics would like to extend our warmest wishes for a joyful holiday season and a healthy, fulfilling new year.

We are deeply grateful to our patients, families, partners, collaborators, researchers, team and the broader scientific community for their dedication and support in advancing the field of mitochondrial therapeutics. Together, we look forward to building on this momentum in the year ahead to bring new hope to patients in need.

#MinoviaTherapeutics #HappyHolidays #SeasonOfGratitude #MitochondrialMedicine

[Minovia Therapeutics @Minovia_tx]

We are pleased and deeply grateful that our work in collaboration with MSKCC and SZMC was nominated among the “Best of ASH 2025” at the American Society of Hematology’s closing session.

The data, presented during the oral session and workshop “Mitochondria and Metabolism: Clinical Trials,” was recognized by meeting organizers among the Best of ASH for its innovative approach to mitochondrial therapy. This recognition highlights groundbreaking pre-clinical and early clinical findings from our collaborations with Memorial Sloan Kettering Cancer Center and Shaare Zedek Medical Center. The studies demonstrated delayed leukemic progression, improved survival in pre-clinical models, and a strong safety profile with encouraging early signs of efficacy in patients.

We are proud of this achievement and remain committed to continuing our work with leading research and clinical partners to advance mitochondrial therapeutics for patients in need.
‌
#MinoviaTherapeutics #ASH25 #BestOfASH #CellTherapy #MitochondrialMedicine #MDS #Hematology

[Minovia Therapeutics @Minovia_tx]

Based on the proven ability of isolated mitochondria to enter cells, we have researched and developed our science of mitochondrial augmentation into a therapeutic platform: Mitochondrial Augmentation Technology (MAT), an investigational, proprietary mitochondrial transplantation approach aimed to treat the root cause of diseases caused by mitochondrial dysfunction.

Learn more: https://t.co/7boCwOvsbw

#MinoviaTherapeutics #Mitochondria #CellularHealth #MitochondrialTherapy #MitochondrialMedicine #Biotechnology

[Minovia Therapeutics @Minovia_tx]

Last week at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, Minovia Therapeutics’ Mitochondrial Augmentation Technology (MAT) was featured in both a presentation and workshop, and was nominated among the “Best of ASH 2025” at the conference’s closing session.

This recognition highlights groundbreaking pre-clinical and early clinical findings from collaborations with Memorial Sloan Kettering Cancer Center and Shaare Zedek Medical Center. The studies demonstrated delayed leukemic progression, improved survival in pre-clinical models, and a strong safety profile with early signs of efficacy in patients.

We are proud of this recognition and remain committed to collaborating with leading research and clinical partners to advance mitochondrial therapeutics for patients in need.

#MinoviaTherapeutics #ASH25 #BestOfASH #CellTherapy #MitochondrialMedicine #MDS #Hematology

[Minovia Therapeutics @Minovia_tx]

3 days away! We’re proud to share that Minovia’s Mitochondrial Augmentation Technology (MAT) will be featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, December 6–9 in Orlando, Florida!

Research conducted at Memorial Sloan Kettering Cancer Center and Shaare Zedek Medical Center demonstrates delayed leukemic progression and improved survival in pre-clinical models, together with a strong safety profile and preliminary efficacy in a Phase 1 trial for myelodysplastic syndrome.

Join the oral presentation on Saturday, Dec 6 at 2:00 PM ET and the “Mitochondria and Metabolism – Clinical Trials” workshop on Friday, Dec 5 at 5:10 PM ET.

To schedule a meeting with our executive team, please email [email protected]

#MinoviaTherapeutics #MitochondrialMedicine #ClinicalResearch #Biotechnology #MyelodysplasticSyndrome #ASH2025

[Minovia Therapeutics @Minovia_tx]

Minovia Therapeutics is leading the way as the first clinical-stage company to harness the therapeutic power of mitochondrial transplantation. Our innovative Mitochondrial Augmentation Therapy (MAT) aims to transform the lives of patients suffering from mitochondrial dysfunction, a root cause of many rare and age-related diseases.

We remain committed to advancing this science-driven platform to bring life-changing therapies to those with unmet medical needs.

Discover more about our journey here: https://t.co/rXwnfYqYFg

#MinoviaTherapeutics #MitochondrialTherapy #CellTherapy #RareDiseases #BiotechInnovation #PrecisionMedicine

[Minovia Therapeutics @Minovia_tx]

Pearson Syndrome and Myelodysplastic Syndrome are both disorders characterized by impaired functionality of hematopoietic stem cells within the blood system. Existing scientific literature demonstrates that mitochondrial dysfunction plays a significant role in the pathophysiology of stem cells involved in both diseases.

Learn more about our MAT platform: https://t.co/UwVZZzNQtn
‌
#MinoviaTherapeutics #MitochondrialScience #CellTherapy #BiotechInnovation #PatientCare #RareDiseases

[Minovia Therapeutics @Minovia_tx]

At Minovia Therapeutics, we recognize mitochondrial dysfunction as a fundamental factor in aging. As the mitochondrial genome accumulates mutations over time, its function declines, contributing to age-related deterioration across multiple organs.

Our mitochondrial augmentation therapy has shown strong early promise. In preclinical studies with aging mice, a single treatment led to a younger kidney profile and increased mitochondrial gene expression within just one month. The mice also exhibited improved mobility, and exploratory behavior, potentially reversing age-related decline.

#MinoviaTherapeutics #LongevityScience #MitochondrialTherapy #RegenerativeMedicine #HealthyAging #BiotechInnovation

[Minovia Therapeutics @Minovia_tx]

Harnessing the revolutionary potential of our proprietary Mitochondrial Augmentation Technology (MAT), we aim to restore cellular energy and function across a broad spectrum of rare genetic and age-related mitochondrial disorders. Our dedicated team works collaboratively with world-leading scientists, clinicians, and patient communities to advance meaningful therapies.

#MinoviaTherapeutics #MitochondrialTherapy #RareDiseases #BiotechInnovation #CellTherapy #PatientDrivenResearch

[Minovia Therapeutics @Minovia_tx]

We are proud to highlight Dr. Natalie Yivgi-Ohana, Co-founder and CEO of Minovia Therapeutics, featured in Authority Magazine's "Inspirational Women in STEM and Tech" series. With more than two decades of expertise in mitochondrial research, Dr. Yivgi-Ohana’s evolution from a biochemistry doctoral scholar to a pioneering leader in biotechnology exemplifies exceptional dedication and innovation.

We invite you to explore her compelling story and the invaluable leadership insights that drive Minovia’s commitment to advancing therapies that offer hope to children and adults affected by mitochondrial diseases globally: https://t.co/E4A0qYxLs9
‌
#MinoviaTherapeutics #WomenInSTEM #Leadership #BiotechInnovation #MitochondrialTherapy #AuthorityMagazine